Vinpocetine-Sar - instructions for use, dose, side effects, contraindications

Composition:Active substance: vinpocetine 0.005 g, Excipients: a sufficient amount to obtain a tablet weighing 0.150 g; potato starch - 0.032 g, milk sugar (lactose) - 0.061 g, microcrystalline cellulose - 0.045 g, giprolose (klocel) 0.003 g, carboxymethyl starch sodium (primogel) 0.003 g, magnesium stearate 0.001 g.

Description:Tablets are white or white with a yellowish tint of color, a flat-cylindrical shape with a bevel.

Pharmacotherapeutic group:Means that improve cerebral blood flow

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:

Vasodilating agent, improving cerebral circulation. Causes a slight decrease in systemic arterial pressure, cerebral vasodilation, increased blood flow and improved supply of brain oxygen and glucose.Increases the resistance of brain cells to hypoxia, facilitating the transport of oxygen and substrates of energy supply to tissues (due to a decrease in the affinity of erythrocytes, increased absorption and glucose metabolism, switching it to an energetically more advantageous aerobic direction). It promotes the accumulation in the tissues of cyclic adenosine monophosphate and adenosine triphosphate (inhibition of phosphodiesterase and stimulation of adenylate cyclase), an increase in the content of catecholamines in the brain tissues.

The vasodilating effect is associated with a direct relaxing effect on the smooth muscles of the vessels of the predominantly brain. Vinpocetine does not cause the phenomenon of "stealing", primarily enhances the blood supply of the ischemic region of the brain, while not changing the blood supply of intact areas. Improves microcirculation in the brain due to a decrease in platelet aggregation, decrease in blood viscosity, increase in the deformability of erythrocytes.

Pharmacokinetics:

When ingested quickly and completely absorbed in the gastrointestinal tract. Bioavailability is about 70%. Time to reach the maximum concentration of the drug in the plasma - 1 hour.The therapeutic concentration in plasma is 10-20 ng / ml. For parenteral administration, the volume of distribution is 5.3 l / kg. The half-life of the drug is 4.74-5 hours. It is excreted by the kidneys and through the intestine in a ratio of 3: 2. Easily penetrates through gistogematicheskie barriers (including blood-brain barrier).

Indications:

Neurology: as a symptomatic agent for various forms of cerebral circulatory insufficiency (ischemic stroke, restorative stage of hemorrhagic stroke, consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, cerebrovascular atherosclerosis, posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of the choroid and retina (including occlusion of the central artery or retinal vein).

Perceptive hearing loss, Meniere's disease, idiopathic tinnitus.

Contraindications:

Hypersensitivity, acute phase of hemorrhagic stroke, severe form of coronary heart disease, severe heart rhythm disturbances, pregnancy, lactation, age under 18,intolerance to fructose, deficiency of 1,6-diphosphatase, lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Carefully:

Use with caution in arrhythmias, angina pectoris, with unstable arterial pressure and reduced vascular tone.

With caution appoint a patient, host antihypertensive drugs or drugs that increase the interval Q - T, as well as patients with poor tolerance of alkaloids Barvinka small (Vinca minor) and suffering from liver failure.

Pregnancy and lactation:Vinpocetine is contraindicated in pregnancy. Data on the safety of Vinpocetine during lactation (breastfeeding) are not available. If you need to use the drug during lactation, you should decide whether to stop breastfeeding.

Dosing and Administration:

The course of treatment and dosage are determined by the attending physician.

In most cases, take 1-2 tablets (5-10 mg) 3 times a day. Vinpocetine-Cap® should be taken after meals.

The maintenance dose is 5 mg 3 times a day for a long time. The course is from 1 to 8 months, on average - 3-4 months.In case of cancellation of the drug, the dose of Vinpocetine-Cap® decrease within 2-3 days.

Side effects:

From the nervous system and sensory organs: dizziness, headache, insomnia, drowsiness, weakness.

Co side of the cardiovascular system and blood (hematopoiesis, hemostasis): slowing of intraventricular conduction; segment depression ST and lengthening the interval QT, hypotension, tachycardia, extrasystole.

On the part of the digestive system: dry mouth, nausea, heartburn.

From the skin: sweating.

Other: allergic reactions.

Overdose:

There are no reports of cases of an overdose of Vinpocetine-Sar®.

Treatment: gastric lavage, reception of activated charcoal, symptomatic treatment.

Interaction:

It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary). Despite the lack of data confirming the possibility of interaction, caution should be exercised when using anti- - arrhythmics and awith anticoagulants.

Special instructions:In case of lactose intolerance, it should be taken into account that each tablet contains 61 mg of lactose.

Use in Pediatrics

Do not recommend prescribing the drug to children under the age of 18 due to a lack of experience with Vinpocetine in this category of patients.

Effect on the ability to drive transp. cf. and fur:

During the period of treatment, it is prohibited to drive vehicles and engage in other potentially dangerous activities that require a high concentration of attention and speed of psychomotor reactions.

Form release / dosage:Tablets 0.005 g.

Packaging:10 tablets in a planar cell package. 2,3, 5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

In dry, protected from light and out of reach of children at a temperature of no higher than 25 ° C.

Shelf life:2 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N002623 / 02

Date of registration:18.09.2008 / 18.09.2015

Expiration Date:Unlimited

The owner of the registration certificate:Promomed Rus, Open CompanyPromomed Rus, Open Company Russia

Manufacturer: & nbsp

BIOCHEMIST, OJSC Russia

Representation: & nbspBIOCHEMICAL JSC BIOCHEMICAL JSC Russia

Information update date: & nbsp19.02.2017

Illustrated instructions

Instructions

Vinpocetine-Sar® (Vinpocetine-Sar)